Sirichai Wilartratsami

Sirichai Wilartratsami

Auto-generated profile, based on publicly available information

Sirichai Wilartratsami

Department of Orthopedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Spine Journal
Verified
Journal Article
Closed access
PLPanya Luksanapruksa
Panya Luksanapruksa
Jacob M BuchowskiJacob M Buchowski
Jacob M Buchowski
WHWilliam Hotchkiss
William Hotchkiss
STSasima Tongsai
Sasima Tongsai
SWSirichai Wilartratsami
Sirichai Wilartratsami
ACAreesak Chotivichit
Areesak Chotivichit

3 June 2024 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
WBWin Boonsirikamchai
Win Boonsirikamchai
SWSirichai Wilartratsami
Sirichai Wilartratsami
MRMonchai Ruangchainikom
Monchai Ruangchainikom
EKEkkapoj Korwutthikulrangsri
Ekkapoj Korwutthikulrangsri
STSasima Tongsai
Sasima Tongsai
PLPanya Luksanapruksa
Panya Luksanapruksa
This study presents a systematic literature review and meta-analysis of pseudarthrosis risk factors following lumbar fusion procedures. The odds ratio (OR) and 95% confidence interval (95% CI) were used for outcome measurements. The objective of this study was to identify the independent risk factors for pseudarthrosis after lumbar spinal fusion, which is crucial for mitigating morbidity and reoperation. Systematic searches in PubMed, Embase, and Scopus (1990–July 2021) were conducted using specific terms. The inclusion criteria included prospective and retrospective cohorts and case‒control series reporting ORs with 95% CIs from multivariate analysis. The quality assessment utilized the Newcastle–Ottawa scale. Meta-analysis, employing OR and 95% CI, assessed pseudarthrosis risk factors in lumbar fusion surgery, depicted in a forest plot. Of the 568 abstracts identified, 12 met the inclusion criteria (9 retrospective, 2006–2021). The 17 risk factors were categorized into clinical, radiographic, surgical, and bone turnover marker factors. The meta-analysis highlighted two significant clinical risk factors: age (95% CI 1.02–1.11; p = 0.005) and smoking (95% CI 1.68–5.44; p = 0.0002). The sole significant surgical risk factor was the number of fused levels (pooled OR 1.35; 95% CI 1.17–1.55; p < 0.0001). This study identified 17 risk factors for pseudarthrosis after lumbar fusion surgery, emphasizing age, smoking status, and the number of fusion levels. Prospective studies are warranted to explore additional risk factors and assess the impact of surgery and graft type.

30 June 2023 in Neurospine
Verified
Journal Article
Open access
PDF file
SSSiravich Suvithayasiri
Siravich Suvithayasiri
YKYoung-Jin Kim
Young-Jin Kim
YLYanting Liu
Yanting Liu
WTWarayos Trathitephun
Warayos Trathitephun
AAAkarawit Asawasaksaku
Akarawit Asawasaksaku
JKJin-Sung Kim
Jin-Sung Kim
Objective: We aim to report the outcomes and feasibility of endoscopic spine surgery used to treat symptomatic spinal metastases patients. This is the most extensive series of spinal metastases patients who underwent endoscopic spine surgery.Methods: A worldwide collaborative network group of endoscopic spine surgeons, named ‘ESSSORG,’ was established. Patients diagnosed with spinal metastases who underwent endoscopic spine surgery from 2012 to 2022 were retrospectively reviewed. All related patient data and clinical outcomes were gathered and analyzed before the surgery and the followtime period of 2 weeks, 1 month, 3 months, and 6 months.Results: A total of 29 patients from South Korea, Thailand, Taiwan, Mexico, Brazil, Argentina, Chile, and India, were included. The mean age was 59.59 years, and 11 of them were female. The total number of decompressed levels was 40. The technique was relatively equal (15 uniportal; 14 biportal). The average length of admission was 4.41 days. Of all patients with an American Spinal Injury Association Impairment Scale of D or lower before surgery, 62.06% reported having at least one recovery grade after the surgery. Almost all clinical outcomes parameters statistically significantly improved and maintained from 2 weeks to 6 months after the surgery. Few surgical-related complications (4 cases) were reported.Conclusion: Endoscopic spine surgery is a valid option for treating spinal metastases patients as it could yield comparable results to other minimally invasive spine surgery techniques. As the aim is to improve the quality of life, this procedure is valuable and holds value in palliative oncologic spine surgery.

28 January 2022 in Spinal Cord Series and Cases
Verified
Journal Article
Closed access
PDF file
CCCholavech Chavasiri
Cholavech Chavasiri
NSNatchaya Suriyachat
Natchaya Suriyachat
PLPanya Luksanapruksa
Panya Luksanapruksa
SWSirichai Wilartratsami
Sirichai Wilartratsami
SCSrinual Chavasiri
Srinual Chavasiri

31 December 2025 in Asian Spine Journal
Verified
Journal Article
Open access
PDF file
CCChatupon Chotigavanichaya
Chatupon Chotigavanichaya
KMKorawish Mekariya
Korawish Mekariya
BSBorriwat Santipas
Borriwat Santipas
SWSirichai Wilartratsami
Sirichai Wilartratsami
EKEkkapoj Korwutthikulrangsri
Ekkapoj Korwutthikulrangsri
PLPanya Luksanapruksa
Panya Luksanapruksa
Study Design: A double-blind randomized placebo-controlled trial.Purpose: To evaluate the efficacy and safety of gabapentin (GBA) and pregabalin (PGB) versus placebo in managing neurogenic intermittent claudication (NIC), functional outcomes, and quality of life in patients with lumbar spinal stenosis (LSS). Overview of Literature: GBA and PGB are frequently prescribed for NIC associated with LSS. However, evidence supporting their efficacy, either in comparison with placebo or in direct comparison between the two gabapentinoids in LSS, remains limited.Methods: LSS patients with predominant NIC symptoms for ≥3 months were randomized (1:1:1) to receive GBA (1,800 mg/day), PGB (300 mg/day), or placebo in addition to standard conservative management, including physical therapy and naproxen. GBA and PGB were both titrated to the effective dose over 14 days. The primary outcome was NIC pain measured by Visual Analog Scale (VAS). Secondary outcomes included the Swiss Spinal Stenosis Score (SSS), self-paced shuttle walk test (SPSWT; time to NIC symptoms and walking distance), Euro-QoL Group’s 5-Dimension, 5-Level (EQ-5D-5L), and adverse effects. All outcomes were assessed monthly over 4 months.Results: Ninety patients (mean age, 63.14 years; symptoms duration, 19.38 months) were included. All groups demonstrated significant improvements in VAS, SSS, SPSWT, and EQ-5D-5L at 4 months. At 1 and 2 months, PGB showed greater EQ-5D-5L improvement compared to GBA (mean differences: 0.07 [p=0.045] and 0.08 [p=0.001], respectively). No significant differences in other outcomes were observed between groups at any time point. Adverse effects, including dizziness and sedation, were more common in the GBA and PGB groups compared to placebo (p<0.001).Conclusions: GBA and PGB did not demonstrate superior efficacy over placebo in reducing NIC and improving functional outcomes in LSS. Moreover, their use was associated with a higher incidence of adverse effects. These findings suggest limited utility for gabapentinoids as adjunctive treatments for LSS.

1 November 2021 in The Spine Journal
Verified
Journal Article
Closed access
PLPanya Luksanapruksa
Panya Luksanapruksa
PPPariwat Phikunsri
Pariwat Phikunsri
WTWarayos Trathitephun
Warayos Trathitephun
BSBorriwat Santipas
Borriwat Santipas
SSSiravich Suvithayasiri
Siravich Suvithayasiri
SWSirichai Wilartratsami
Sirichai Wilartratsami